Biomedical Engineering Advancements after Management of Myelomeningocele Study (MOMS): A Narrative Review

Authors

DOI:

https://doi.org/10.5195/ijms.2022.1127

Keywords:

Myelomeningocele, Fetoscopic Surgery, Tissue Engineering, Tissue Scaffolds, Neural Tube Defect

Abstract

Spina bifida is a neural tube defect resulting from an incomplete closure of the caudal neuropore. The most debilitating form of spina bifida, myelomeningocele (MMC), can present with Chiari II malformation with concomitant hydrocephalus, bowel and bladder abnormalities, and impaired motor function of the lower limbs. The incidence rate of spina bifida is 3.4 per 10,000 live births reported within the US. Advancements in the standard therapy, namely prenatal intervention pioneered by the Management of Myelomeningocele Study (MOMS), have aimed to reduce maternal and fetal complications, and yet complications were increased, calling for the need of further improvements. Beyond current standard interventions for MMC, the most promising developments have employed various biomedical methods ranging from isolated stem cell injections to biodegradable scaffold patches. These scaffolds can be biologic or synthetic and are often incorporated with bioactive proteins or stem cells. This review discusses the benefits and limitations of post-MOMS era biomedical engineering intervention articles found in 3 medical and biomedical databases consisting of systematic reviews, meta-analyses, randomized control trials, and experimental studies. After analysis of the advancements and limitations of these studies, an engineered synthetic biodegradable scaffold seeded with bioactive proteins and stem cells create a superior scaffold possessing watertight impermeability and cytocompatibility for successful coverage and host integration with minimal inflammation. Coupled with minimally invasive intra-amniotic injection delivery, an earlier mitigation could further prevent progression of poor neurologic outcomes, and possibly even regenerate neuronal tissue in patients with MMC.

Metrics

Metrics Loading ...

References

Rochelle D, Frando M, Voto H, Baron K. Pediatric Rehabilitation. In: Maitin IB, Cruz E, editors. CURRENT Diagnosis & Treatment: Physical Medicine & Rehabilitation Eds. New York: McGraw-Hill; 2014.

Moldenhauer JS, Flake AW. Open fetal surgery for neural tube defects. Best Practice & Research Clinical Obstetrics & Gynaecology. 2019 Jul 1;58:121-32.

Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck GN, Shaw GM. Spina bifida. Nature reviews Disease primers. 2015 Apr 30;1(1):1-8.

Castillo J, Lupo PJ, Tu DD, Agopian AJ, Castillo H. The National Spina Bifida Patient Registry: A Decade's journey. Birth defects research. 2019 Aug 15;111(14):947-57.

Williams J, Mai CT, Mulinare J, Isenburg J, Flood TJ, Ethen M, et al. Updated estimates of neural tube defects prevented by mandatory folic acid fortification—United States, 1995–2011. MMWR. Morbidity and mortality weekly report. 2015 Jan 16;64(1):1.

Adzick NS, Thom EA, Spong CY, Brock III JW, Burrows PK, Johnson MP, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. New England Journal of Medicine. 2011 Mar 17;364(11):993-1004.

Adzick N. S. (2012). Fetal surgery for myelomeningocele: trials and tribulations. Isabella Forshall Lecture. Journal of pediatric surgery, 47(2), 273–281.

Moldenhauer JS, Adzick NS. Fetal surgery for myelomeningocele: After the Management of Myelomeningocele Study (MOMS). In Seminars in Fetal and Neonatal Medicine. 2017 Dec 1; 22(6), 360-66.

Watanabe M, Jo JI, Radu A, Kaneko M, Tabata Y, Flake AW. A tissue engineering approach for prenatal closure of myelomeningocele with gelatin sponges incorporating basic fibroblast growth factor. Tissue Engineering Part A. 2010 May 1;16(5):1645-55.

Watanabe M, Li H, Roybal J, Santore M, Radu A, Jo JI, et al. A tissue engineering approach for prenatal closure of myelomeningocele: comparison of gelatin sponge and microsphere scaffolds and bioactive protein coatings. Tissue Engineering Part A. 2011 Apr 1;17(7-8):1099-110.

Watanabe M, Li H, Kim AG, Weilerstein A, Radu A, Davey M, et al. Complete tissue coverage achieved by scaffold-based tissue engineering in the fetal sheep model of Myelomeningocele. Biomaterials. 2016 Jan 1;76(1):133-43.

Brown EG, Saadai P, Pivetti CD, Beattie MS, Bresnahan JC, Wang A, et al. In utero repair of myelomeningocele with autologous amniotic membrane in the fetal lamb model. J Pediatr Surg. 2014; 49(1):133-38.

Brown EG, Keller BA, Lankford L, Pivetti CD, Hirose S, Farmer DL, et al. Age does matter: a pilot comparison of placenta-derived stromal cells for in utero repair of myelomeningocele using a lamb model. Fetal diagnosis and therapy. 2016;39(3):179-85.

Brown EG, Keller BA, Pivetti CD, Sitkin NA, Farmer DL, Bresnahan JC: Development of a locomotor rating scale for testing motor function in sheep. J Pediatr Surg. 2015;50(1):617-21.

Li X, Yuan Z, Wei X, Li H, Zhao G, Miao J, et al. Application potential of bone marrow mesenchymal stem cell (BMSCs) based tissue-engineering for spinal cord defect repair in rat fetuses with spina bifida aperta. Journal of Materials Science: Materials in Medicine. 2016 Apr 1;27(4):77.

Dionigi B, Brazzo III JA, Ahmed A, Feng C, Wu Y, Zurakowski D, et al. Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida. Journal of pediatric surgery. 2015 Jun 1;50(6):1037-41.

Feng C, Graham CD, Connors JP, Brazzo III J, Zurakowski D, Fauza DO. A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida. Journal of pediatric surgery. 2016 Jun 1;51(6):1010-13.

Annor AH, Tang ME, Pui CL, Ebersole GC, Frisella MM, Matthews BD, et al. Effect of enzymatic degradation on the mechanical properties of biological scaffold materials. Surgical endoscopy. 2012 Oct;26(10):2767-78.

Oria M, Tatu RR, Lin CY, Peiro JL. In vivo evaluation of novel PLA/PCL polymeric patch in rats for potential spina bifida coverage. Journal of surgical research. 2019 Oct 1;242:62-9.

Matta AK, Rao RU, Suman KN, Rambabu V. Preparation and characterization of biodegradable PLA/PCL polymeric blends. Procedia materials science. 2014 Jan 1;6(1):1266-70.

Tatu R, Oria M, Pulliam S, Signey L, Rao MB, Peiro JL, et al. Using poly (l‐lactic acid) and poly (ɛ‐caprolactone) blends to fabricate self‐expanding, watertight and biodegradable surgical patches for potential fetoscopic myelomeningocele repair. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2019 Feb;107(2):295-305.

Kunpalin Y, Subramaniam S, Perin S, Gerli MF, Bosteels J, Ourselin S, Deprest J, De Coppi P, David AL. Preclinical stem cell therapy in fetuses with myelomeningocele: A systematic review and meta‐analysis. Prenatal diagnosis. 2021 Feb;41(3):283-300.

Boehler RM, Graham JG, Shea LD. Tissue engineering tools for modulation of the immune response. Biotechniques. 2011 Oct;51(4):239-54.

Bergh E, Buskmiller C, Johnson A. The Future of Fetal Surgery. Obstetrics and Gynecology Clinics. 2021 Dec;48(4):745-58.

Downloads

Published

2022-04-25 — Updated on 2023-01-02

How to Cite

Campbell, N. C., Trippel, S. B., & Nauman, E. A. (2023). Biomedical Engineering Advancements after Management of Myelomeningocele Study (MOMS): A Narrative Review. International Journal of Medical Students, 10(4), 405–412. https://doi.org/10.5195/ijms.2022.1127

Issue

Vol. 10 No. 4 (2022)

Section

Review

Categories

License

Copyright (c) 2022 Natalie C. Campbell, Stephen B. Trippel, Eric A. Nauman

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org